Prolgolimab with Chemotherapy as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer

Prolgolimab is an IgG1 anti-PD-1 monoclonal antibody with the Fc-silencing ‘LALA’ mutation. The phase III DOMAJOR study assessed efficacy and safety of prolgolimab in combination with pemetrexed and platinum-based chemotherapy vs placebo in combination with pemetrexed and platinum-based chemotherapy...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of cancer (1990) 2025-01, Vol.217, p.115255, Article 115255
Hauptverfasser:	Laktionov, K., Smolin, A., Stroyakovskiy, D., Moiseenko, V., Dvorkin, M., Andabekov, T., Cheng, Y., Liu, B., Kozlov, V., Odintsova, S., Dvoretsky, S., Mochalova, A., Urda, M., Yi, T., Li, X., László, U., Müller, V., Bogos, K., Fadeeva, N., Musaev, G., Liu, Q., Kirtbaya, D., Shi, J., Gladkov, O., Narimanov, M., Semiglazova, T., Khasanova, A., Chovanec, J., Andrašina, I., Szabová, A., Rosinská, O., Sudekova, D., Zsolt, P-S., Ran, F., Sun, M., Jiang, O., Chen, R., Zhao, E., Liu, C., Tan, W., Pirmagomedov, A., Poddubskaya, E., Kislov, N., Shumskaya, I., Sorokina, I., Zinkina-Orikhan, A., Linkova, Yu, Fogt, S., Liaptseva, D., Siliutina, A., Basova, O., Kryukov, F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-PD-1 Non-small cell lung cancer PD-L1 expression Prolgolimab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!